Table 2. Effect of individual risk factors on overall survival and identification of prognostic variables.
| Patients (n) | Risk population | Risk of patients with non-advanced mastocytosis |
Risk of patients with advanced systemic mastocytosis |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis |
Multivariate analysis |
Univariate analysis |
Multivariate analysis |
|||||||
| HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | |||
| Male sex | 1641 | ·· | 2·01 (1·14–3·55) | 0·016 | 1·47 (0·67–3·14) | 0·35 | 1·74 (1·20–2·54) | 0·004 | 1·12 (0·67–1·86) | 0·48 |
|
| ||||||||||
| Age (years) | 1641 | ≥60 | 1·11 (1·08–1·14) | <0·0001 | 10·75 (5·68–20·32) | <0·0001 | 1·04 (1·03–1·06) | <0·0001 | 2·14 (1·42–3·22) | <0·0001 |
|
| ||||||||||
| Tryptase (ng/mL) | 1530 | ≥125 | 3·01 (1·59–5·70) | <0·0001 | 1·61 (0·72–3·72) | 0·24 | 1·66 (1·18–2·35) | 0·0004 | 1·81 (1·20–2·75) | 0·005 |
|
| ||||||||||
| Leukocytes (× 109 per L) | 1543 | ≥16 | 2·08 (0·26–16·65) | 0·491 | ·· | ·· | 1·94 (1·20–3·14) | 0·007 | 1·88 (1·27–2·79) | 0·002 |
|
| ||||||||||
| Haemoglobin (g/dL) | 1550 | ≤11·0 | 0·01 (0·00–0·31) | 0·019 | ·· | ·· | 0·01 (0·00–0·04) | <0·0001 | 1·71 (1·13–2·57) | 0·011 |
|
| ||||||||||
| Platelets (× 109 per L) | 1543 | ≤100 | 0·05 (0·01–0·23) | <0·0001 | 5·78 (0·56–59·52) | 0·14 | 0·17 (0·11–0·27) | <0·0001 | 1·63 (1·13–2·34) | 0·009 |
|
| ||||||||||
| Lactate dehydrogenase (U/L) | 1226 | ≥260 | 0·46 (0·04–5·29) | 0·535 | ·· | ·· | 2·51 (1·27–4·98) | 0·008 | 1·36 (0·82–2·28) | 0·19 |
|
| ||||||||||
| Alkaline phosphatase (U/L) | 1295 | ≥100 | 15·19 (3·93–58·71) | <0·0001 | 2·91 (1·60–5·30) | <0·0001 | 2·16 (1·35–3·46) | 0·001 | 0·74 (0·39–1·40) | 0·11 |
|
| ||||||||||
| Calcium (mg/dL) | 1216 | ≤8·7 | 0·01 (0·00–0·01) | 0·003 | 0·97 (0·22–4·22) | 0·93 | 0·01 (0·00–0·01) | <0·0001 | 1·48 (0·91–2·41) | 0·12 |
|
| ||||||||||
| Neutrophils (%) | 1466 | ≥50 | 11·11 (0·72–171·57) | 0·085 | 2·58 (0·90–7·44) | 0·081 | 0·66 (0·30–1·46) | 0·307 | ·· | ·· |
|
| ||||||||||
| Monocytes (%) | 1420 | ≥0·32 | 16·74 (0·19–1451·66) | 0·216 | ·· | ·· | 3·20 (1·06–9·69) | 0·040 | 1·43 (0·53–3·83) | 0·44 |
|
| ||||||||||
| Eosinophils granulocytes (%) | 1432 | ·· | 1·01 (0·94–1·10) | 0·749 | ·· | ·· | 1·00 (0·99–1·02) | 0·408 | ·· | ·· |
|
| ||||||||||
| Skin involvement | 1641 | ·· | 1·06 (0·50–2·28) | 0·877 | ·· | ·· | 0·44 (0·31–0·65) | <0·0001 | 0·46 (0·30–0·69) | <0·0001 |
|
| ||||||||||
| Organomegaly* | 1464 | ·· | 3·05 (1·56–5·94) | 0·001 | 1·28 (0·56–2·94) | 0·51 | 1·06 (0·68–1·66) | 0·782 | ·· | ·· |
|
| ||||||||||
| Mediator symptoms | 1639 | ·· | 0·66 (0·36–1·20) | 0·171 | ·· | ·· | 0·61 (0·43–0·85) | 0·004 | 0·87 (0·52–1·48) | 0·25 |
|
| ||||||||||
| Allergy | 1418 | ·· | 0·74 (0·39–1·43) | 0·376 | ·· | ·· | 0·43 (0·22–0·84) | 0·014 | 0·48 (0·20–1·19) | 0·23 |
Prognostic variables were examined for their statistical power and independence from each other and from the WHO classification by univariate and multivariate analysis. HR=hazard ratio.
*
Organomegaly (ie, enlarged spleen, enlarged liver, enlarged lymph nodes, or a combination).